ImmVirX and Innovent Enter into Clinical Trial Collaboration to Investigate the Combination of IVX037 and Sintilimab in Difficult-to-treat Cancers
ImmVirX’s Oncolytic Virus IVX037 to be assessed in combination with Innovent’s checkpoint inhibitor TYVYT® in Colorectal, Ovarian and Gastric Cancer to Investigate the Combination of IVX037 and Sintilimab in Difficult-to-treat Cancers Melbourne, Australia 21st February 2024 – ImmVirX Pty Limited, a life sciences company dedicated to pioneering the next generation of receptor-targeted immunotherapies for patients […]
ImmVirX receives $3.77M R&D tax refund for FY23
Melbourne, Australia 12 February 2024 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, has received a $3,771,296 Research and Development (R&D) tax refund as part of the Australian Federal Government’s R&D […]
CEO Malcolm McColl speaks at Bell Potter Healthcare Conference
ImmVirX is pleased to advise that Co-Founder and CEO Dr Malcolm McColl’s presentation at the Bell Potter Healthcare Conference 2023 held in November is available to view here.
ImmVirX reports on operations for FY23
Melbourne, Australia 21 September 2023 – ImmVirX Pty Limited, a life sciences company dedicated to pioneering the next wave of receptor-targeted oncolytic viral immunotherapies for patients confronted with common yet formidable cancers, presents a summary of its operations for the financial year ending 30 June 2023. The year was headlined by the progress of IVX037, ImmVirX’s […]
